About
Periodic safety update report single assessments (PSUSAs) are single assessments of related periodic safety update reports (PSURs) for active substances contained in medicines authorised in the European Union (EU). A PSUR is a pharmacovigilance report submitted regularly by a marketing-authorisation holder at defined time points following a medicine's authorisation.
Key facts
- Active substance(s) in scope of the PSUSA procedure
- Leuprorelin (depot formulations)
- Procedure number
- PSUSA/00010877/202107
- Regulatory outcome
- Variation
Documents
Leuprorelin (depot formulations) : List of nationally authorised medicinal products - PSUSA/00010877/202107
English (EN) (275.79 KB - PDF)
Leuprorelin (depot formulations) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010877/202107
English (EN) (149.1 KB - PDF)
български (BG) (158.7 KB - PDF)
español (ES) (147.43 KB - PDF)
čeština (CS) (183.43 KB - PDF)
dansk (DA) (130.63 KB - PDF)
Deutsch (DE) (138.38 KB - PDF)
eesti keel (ET) (165.42 KB - PDF)
ελληνικά (EL) (168.17 KB - PDF)
français (FR) (131.76 KB - PDF)
hrvatski (HR) (213.37 KB - PDF)
íslenska (IS) (125.92 KB - PDF)
italiano (IT) (175.07 KB - PDF)
latviešu valoda (LV) (215.31 KB - PDF)
lietuvių kalba (LT) (213.65 KB - PDF)
magyar (HU) (204.54 KB - PDF)
Malti (MT) (211.84 KB - PDF)
Nederlands (NL) (133.83 KB - PDF)
norsk (NO) (128.53 KB - PDF)
polski (PL) (182.34 KB - PDF)
português (PT) (146.35 KB - PDF)
română (RO) (195.06 KB - PDF)
slovenčina (SK) (221.33 KB - PDF)
slovenščina (SL) (184.46 KB - PDF)
Suomi (FI) (124.39 KB - PDF)
svenska (SV) (145.47 KB - PDF)